panitumumab
- Generic Name
- panitumumab
- Brand Names
- Vectibix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 339177-26-3
- Unique Ingredient Identifier
- 6A901E312A
- Background
Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.
Panitumumab was granted FDA approval on 27 September 2006.
- Indication
美国FDA批准：用于野生型KRAS(外显子2)转移性结直肠癌(mCRC)患者的一线治疗。
- Associated Conditions
- Metastatic Colorectal Cancer (CRC)
- Associated Therapies
- -
Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1186
- Registration Number
- NCT00339183
PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-06-27
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1053
- Registration Number
- NCT00115765
Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-06-13
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- Amgen
- Registration Number
- NCT00113776
Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-06-13
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 463
- Registration Number
- NCT00113763
Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-05-26
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 150
- Registration Number
- NCT00111774
ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-01-19
- Last Posted Date
- 2010-10-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 50
- Registration Number
- NCT00101920
Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-09-21
- Last Posted Date
- 2009-07-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 86
- Registration Number
- NCT00091806
Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2004-08-11
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 203
- Registration Number
- NCT00089635
ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-05-22
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Abgenix
- Target Recruit Count
- 50
- Registration Number
- NCT00061126
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸UCLA School of Medicine, Los Angeles, California, United States
🇺🇸University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Phase 2
Completed
- Conditions
- First Posted Date
- 2002-04-26
- Last Posted Date
- 2007-12-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 194
- Registration Number
- NCT00034346
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath